Cardinal Health Extends Key CVS Distribution Agreement Through 2032 and Reaffirms Long-Term EPS Guidance

Event Overview

On October 1, 2026, Cardinal Health, Inc. filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) disclosing the execution of a binding Letter of Intent (LOI) to extend its core pharmaceutical distribution agreements with CVS Health through June 30, 2032.

Strategic and Commercial Significance

• Long-Term Revenue Visibility: CVS Health is one of Cardinal Health's largest enterprise customers. Securing a long-term commitment through mid-2032 significantly de-risks customer renewal concerns and confirms the continuation of Cardinal Health's current scope of distribution services.
• Guidance Reaffirmation: Alongside the contract extension, Cardinal Health reaffirmed:
  • FY 2027 Non-GAAP EPS Guidance: $12.40 to $12.60, representing 13% to 15% year-over-year growth (based on adjusted FY26 results).
  • Long-Term Non-GAAP EPS Growth: Target growth rate remains 12% to 14% annually.
• Upcoming Catalysts: Management indicated additional operational details may be shared during the Q1 earnings conference call scheduled for November 5, 2026.